What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (≥10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer
Year: 2022
Type: article
Abstract: OBJECTIVE: Patients with advanced epithelial ovarian cancer (EOC) alive without progression at a landmark time-point of 10 years from diagnosis are likely cured. We report the proportion of patients with Stage III EOC who were long-term disease-free survivors (LTDFS≥10 years) following either intraperitoneal (IP) or intravenous (IV) chemotherapy as well as the predictors of LTDFS. METHODS: Data from 3 mature NRG/GOG trials (104, 114, 172) were analyzed and included demographics, clinicopathologic details, route of administration, and survival outcomes of patients living ≥10 years assessed according to the Kaplan-Meier method. Cox regression survival analysis was performed to evaluate independent prognostic predictors of LTDFS. RESULTS: Of 1174 patients randomized, 10-year overall survival (OS) was 26% (95% CI, 23-28%) and LTDFS ≥10 years was 18% (95% CI, 16-20%). Patients with LTDFS ≥10 years had a median age of 54.6 years (p < 0.001). Younger age (p < 0.001) was the only independent prognostic factor for LTDFS≥10 years on multivariate Cox analysis. CONCLUSIONS: Approximately 18% of patients were LTDFS ≥10 years. They form the tail end of the survival curve and are likely cured. Our results provide a comparative benchmark to evaluate the impact of PARP inhibitors in 1st line maintenance trials on survival outcomes.
Source: Gynecologic Oncology
Authors: Omali Pitiyarachchi, Michael Friedlander, James J. Java, John K. Chan, Deborah K. Armstrong, Maurie Markman, Thomas J. Herzog, Bradley J. Monk, Floor Backes, Angeles Alvarez Secord, Albert Bonebrake, Peter G. Rose, Krishnansu S. Tewari, Samuel S. Lentz, Melissa A. Geller, Larry J. Copeland, Robert S. Mannel
Institutions: UNSW Sydney, Prince of Wales Hospital, University of Rochester Medicine, University of California, San Francisco, Johns Hopkins University, Cancer Treatment Centers of America, University of Cincinnati, Creighton University, University of Arizona, The Ohio State University, Duke University, Duke Medical Center, Duke Cancer Institute, Cancer Research for the Ozarks, CoxHealth, Cleveland Clinic, University of California, Irvine, Atrium Health Wake Forest Baptist, University of Minnesota, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University Wexner Medical Center, University of Oklahoma Health Sciences Center
Language: English
Subfield: Reproductive Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,020
OpenAlex ID: W4285034856